| External factors: | SRM1649b |
| Aging type: | Accelerate |
| Aging characteristic: |
| Category: | Chemical compounds |
| Phenotype: | Aging |
| Experiment: | CCK-8 assay//SA-β-gal activity assay//FACS analysis |
| Description: | The proliferation ability of these two skin cell lines was gradually decreased when the concentration was increased;When detecting the cell cycle distributions following SRM1649b treatment, we found that cells undergone significant G1 phase arrest ;We determined the cell aging by using senescence-associated β-gal staining assay.When treated with low-dose SRM1649b, NHDF cells clearly showed elevated number and proportion of aging cells. |
| Target gene: | CYP1A1//MMP1 |
| R-EF-Target gene: | Upregulation//Upregulation |
| Official symbol(s): | CYP1A1//MMP1 |
| Target gene experiment: | RT-PCR |
| Target gene description: | RT-PCR data showed the level of CYP1A1 and MMP1 mRNA was dramatically increased after increasing concentrations of SRM1649b treatment for 24 h. |
| Regulatory pathway: | AhR-MAPKs |
| R-EF-Pathway: | Activation |
| Official symbol(s): | AHR-MAPK1 |
| Pathway experiment: | Western blot |
| Pathway description: | We found that the protein level of AhR was gradually degraded after increasing concentrations of SRM1649b treatment for 24 h. In contrast, we found that the phosphorylation level of ERK kinase was gradually increased at the same condition, which was consistent with previously reported that the activation of MAPKs pathway might be regarded for AhR degradation. |
Annotation: